NCT00887640View on ClinicalTrials.gov

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Temsirolimus

dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression

DRUG

Diphenhydramine

Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion

Trial Locations (2)

23502

Virginia Oncology Associates, Norfolk

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Duke University

OTHER